New Advances in Radioimmunotherapy for the Treatment of Cancers View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2014-11-14

AUTHORS

Françoise Kraeber-Bodéré , Caroline Bodet-Milin , Caroline Rousseau , Thomas Carlier , Ludovic Ferrer , Nicolas Chouin , Férid Haddad , François Davodeau , Jean-François Chatal , Alain Faivre-Chauvet , Jean-François Gestin , Michel Chérel , Jacques Barbet

ABSTRACT

Radioimmunotherapy (RIT) has been in use for more than 20 years and has progressed significantly with the discovery of new molecular targets, the development of new stable chelates, the humanization of monoclonal antibodies (mAbs), and the use of pretargeting techniques. Today, two products targeting the CD20 antigen are approved in the treatment of B cell lymphoma: 131I-tositumomab (Bexxar®) and 90Y-ibritumomab tiuxetan (Zevalin®). RIT can be integrated in clinical practice for treatment of patients with relapsed or refractory follicular lymphoma (FL) or as consolidation after induction chemotherapy in frontline treatment in FL patients. High-dose treatment, RIT as consolidation, RIT in first-line treatment, fractionated RIT, and use of new humanized mAbs, in particular targeting CD22, showed promising results in B cell lymphoma. In other hemopathies, such as multiple myeloma, efficacy has been demonstrated in preclinical studies. In solid tumors, more resistant to radiations and less accessible to large molecules such as mAbs, clinical efficacy remains limited. However, RIT used in minimal or small-size metastatic disease has shown promising clinical efficacy. Pretargeting approaches have been potential in increasing the therapeutic index of radiolabeled antibodies. Finally, new beta emitters such as lutetium-177 with better physical properties will further improve the safety of RIT. Moreover, alpha emitters such as bismuth-213 or astatine-211 offer the theoretical possibility to eradicate the last microscopic clusters of tumor cells, in the setting of consolidation. Personalized dosimetry protocols, particularly based on quantitative positron emission tomography (PET) imaging, should be developed to optimize injected activity. More... »

PAGES

441-460

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-662-44946-2_25

DOI

http://dx.doi.org/10.1007/978-3-662-44946-2_25

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034466597


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France", 
            "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kraeber-Bod\u00e9r\u00e9", 
        "givenName": "Fran\u00e7oise", 
        "id": "sg:person.0653324404.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bodet-Milin", 
        "givenName": "Caroline", 
        "id": "sg:person.01212260416.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212260416.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
            "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rousseau", 
        "givenName": "Caroline", 
        "id": "sg:person.01240530667.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carlier", 
        "givenName": "Thomas", 
        "id": "sg:person.01200407127.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200407127.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
            "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrer", 
        "givenName": "Ludovic", 
        "id": "sg:person.01112242163.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112242163.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AMaROC Research Group, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Site de la Chantrerie \u2013 CS 40706, 44307, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.418682.1", 
          "name": [
            "Department of Physics, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Site de la Chantrerie, Route de Gachet, 44300, Nantes, France", 
            "AMaROC Research Group, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Site de la Chantrerie \u2013 CS 40706, 44307, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chouin", 
        "givenName": "Nicolas", 
        "id": "sg:person.01244363026.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244363026.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GIP Arronax, 1, rue Aronnax \u2013 CS 10112, 44817, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Physics, Subatech, Ecole des M\u00eenes, University of Nantes, Site de la Chantrerie 4 rue Alfred Kastler, BP 20722, 44307, Nantes, France", 
            "GIP Arronax, 1, rue Aronnax \u2013 CS 10112, 44817, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haddad", 
        "givenName": "F\u00e9rid", 
        "id": "sg:person.01225557150.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225557150.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Oncology, Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Department of Nuclear Oncology, Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davodeau", 
        "givenName": "Fran\u00e7ois", 
        "id": "sg:person.01105624024.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105624024.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GIP Arronax, 1, rue Aronnax \u2013 CS 10112, 44817, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "GIP Arronax, 1, rue Aronnax \u2013 CS 10112, 44817, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chatal", 
        "givenName": "Jean-Fran\u00e7ois", 
        "id": "sg:person.0623457423.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623457423.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
            "Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faivre-Chauvet", 
        "givenName": "Alain", 
        "id": "sg:person.01334456404.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334456404.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Department of Nuclear Oncology, INSERM UMR892 - CNRS UMR6299 - CRCNA (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, 8 quai Moncousu, BP 70721, 44007, Nantes, France", 
            "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gestin", 
        "givenName": "Jean-Fran\u00e7ois", 
        "id": "sg:person.01025400253.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025400253.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM UMR892 - CNRS UMR6299 - CRCNA (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, 8 quai Moncousu, BP 70721, 44007, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
            "Department of Nuclear Medicine, ICO-Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France", 
            "INSERM UMR892 - CNRS UMR6299 - CRCNA (Equipe 13), Institut de Recherche en Sant\u00e9 de l\u2019Universit\u00e9 de Nantes, 8 quai Moncousu, BP 70721, 44007, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ch\u00e9rel", 
        "givenName": "Michel", 
        "id": "sg:person.01224071104.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224071104.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GIP Arronax, 1, rue Aronnax \u2013 CS 10112, 44817, Saint-Herblain, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Nuclear Oncology, Centre de Recherche en Canc\u00e9rologie de Nantes-Angers Inserm, Universit\u00e9 de Nantes, U892 8 quai Moncousu, 44007, Nantes, France", 
            "GIP Arronax, 1, rue Aronnax \u2013 CS 10112, 44817, Saint-Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barbet", 
        "givenName": "Jacques", 
        "id": "sg:person.01001654663.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2014-11-14", 
    "datePublishedReg": "2014-11-14", 
    "description": "Radioimmunotherapy (RIT) has been in use for more than 20 years and has progressed significantly with the discovery of new molecular targets, the development of new stable chelates, the humanization of monoclonal antibodies (mAbs), and the use of pretargeting techniques. Today, two products targeting the CD20 antigen are approved in the treatment of B cell lymphoma: 131I-tositumomab (Bexxar\u00ae) and 90Y-ibritumomab tiuxetan (Zevalin\u00ae). RIT can be integrated in clinical practice for treatment of patients with relapsed or refractory follicular lymphoma (FL) or as consolidation after induction chemotherapy in frontline treatment in FL patients. High-dose treatment, RIT as consolidation, RIT in first-line treatment, fractionated RIT, and use of new humanized mAbs, in particular targeting CD22, showed promising results in B cell lymphoma. In other hemopathies, such as multiple myeloma, efficacy has been demonstrated in preclinical studies. In solid tumors, more resistant to radiations and less accessible to large molecules such as mAbs, clinical efficacy remains limited. However, RIT used in minimal or small-size metastatic disease has shown promising clinical efficacy. Pretargeting approaches have been potential in increasing the therapeutic index of radiolabeled antibodies. Finally, new beta emitters such as lutetium-177 with better physical properties will further improve the safety of RIT. Moreover, alpha emitters such as bismuth-213 or astatine-211 offer the theoretical possibility to eradicate the last microscopic clusters of tumor cells, in the setting of consolidation. Personalized dosimetry protocols, particularly based on quantitative positron emission tomography (PET) imaging, should be developed to optimize injected activity.", 
    "editor": [
      {
        "familyName": "Rezaei", 
        "givenName": "Nima", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-662-44946-2_25", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-662-44945-5", 
        "978-3-662-44946-2"
      ], 
      "name": "Cancer Immunology", 
      "type": "Book"
    }, 
    "keywords": [
      "B-cell lymphoma", 
      "clinical efficacy", 
      "cell lymphoma", 
      "follicular lymphoma", 
      "refractory follicular lymphoma", 
      "safety of radioimmunotherapy", 
      "first-line treatment", 
      "promising clinical efficacy", 
      "treatment of patients", 
      "high-dose treatment", 
      "positron emission tomography (PET) imaging", 
      "Emission Tomography Imaging", 
      "new molecular targets", 
      "induction chemotherapy", 
      "metastatic disease", 
      "FL patients", 
      "frontline treatment", 
      "treatment of cancer", 
      "CD20 antigen", 
      "multiple myeloma", 
      "quantitative positron emission tomography (PET) imaging", 
      "preclinical studies", 
      "humanized mAb", 
      "therapeutic index", 
      "clinical practice", 
      "solid tumors", 
      "bismuth-213", 
      "injected activity", 
      "radioimmunotherapy", 
      "tumor cells", 
      "monoclonal antibodies", 
      "lymphoma", 
      "tomography imaging", 
      "lutetium-177", 
      "molecular targets", 
      "pretargeting approach", 
      "treatment", 
      "patients", 
      "efficacy", 
      "astatine-211", 
      "antibodies", 
      "mAbs", 
      "microscopic clusters", 
      "tiuxetan", 
      "chemotherapy", 
      "myeloma", 
      "new advances", 
      "tumors", 
      "hemopathies", 
      "cancer", 
      "antigen", 
      "CD22", 
      "disease", 
      "promising results", 
      "beta emitters", 
      "alpha emitters", 
      "use", 
      "safety", 
      "imaging", 
      "cells", 
      "years", 
      "setting", 
      "consolidation", 
      "index", 
      "target", 
      "activity", 
      "study", 
      "protocol", 
      "advances", 
      "practice", 
      "dosimetry protocols", 
      "development", 
      "theoretical possibility", 
      "discovery", 
      "humanization", 
      "results", 
      "molecules", 
      "possibility", 
      "radiation", 
      "technique", 
      "large molecules", 
      "stable chelates", 
      "approach", 
      "products", 
      "clusters", 
      "today", 
      "good physical properties", 
      "properties", 
      "chelates", 
      "physical properties", 
      "emitters"
    ], 
    "name": "New Advances in Radioimmunotherapy for the Treatment of Cancers", 
    "pagination": "441-460", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034466597"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-662-44946-2_25"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-662-44946-2_25", 
      "https://app.dimensions.ai/details/publication/pub.1034466597"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_52.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-662-44946-2_25"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-662-44946-2_25'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-662-44946-2_25'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-662-44946-2_25'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-662-44946-2_25'


 

This table displays all metadata directly associated to this object as RDF triples.

257 TRIPLES      22 PREDICATES      115 URIs      108 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-662-44946-2_25 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N8b9d7811e9254c60a5bfe1d8d98000cc
4 schema:datePublished 2014-11-14
5 schema:datePublishedReg 2014-11-14
6 schema:description Radioimmunotherapy (RIT) has been in use for more than 20 years and has progressed significantly with the discovery of new molecular targets, the development of new stable chelates, the humanization of monoclonal antibodies (mAbs), and the use of pretargeting techniques. Today, two products targeting the CD20 antigen are approved in the treatment of B cell lymphoma: 131I-tositumomab (Bexxar®) and 90Y-ibritumomab tiuxetan (Zevalin®). RIT can be integrated in clinical practice for treatment of patients with relapsed or refractory follicular lymphoma (FL) or as consolidation after induction chemotherapy in frontline treatment in FL patients. High-dose treatment, RIT as consolidation, RIT in first-line treatment, fractionated RIT, and use of new humanized mAbs, in particular targeting CD22, showed promising results in B cell lymphoma. In other hemopathies, such as multiple myeloma, efficacy has been demonstrated in preclinical studies. In solid tumors, more resistant to radiations and less accessible to large molecules such as mAbs, clinical efficacy remains limited. However, RIT used in minimal or small-size metastatic disease has shown promising clinical efficacy. Pretargeting approaches have been potential in increasing the therapeutic index of radiolabeled antibodies. Finally, new beta emitters such as lutetium-177 with better physical properties will further improve the safety of RIT. Moreover, alpha emitters such as bismuth-213 or astatine-211 offer the theoretical possibility to eradicate the last microscopic clusters of tumor cells, in the setting of consolidation. Personalized dosimetry protocols, particularly based on quantitative positron emission tomography (PET) imaging, should be developed to optimize injected activity.
7 schema:editor N9957f0500ab44e2cb6a86518bacedff3
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Na45d50cf74394a5bbdb26685e59e3919
11 schema:keywords B-cell lymphoma
12 CD20 antigen
13 CD22
14 Emission Tomography Imaging
15 FL patients
16 activity
17 advances
18 alpha emitters
19 antibodies
20 antigen
21 approach
22 astatine-211
23 beta emitters
24 bismuth-213
25 cancer
26 cell lymphoma
27 cells
28 chelates
29 chemotherapy
30 clinical efficacy
31 clinical practice
32 clusters
33 consolidation
34 development
35 discovery
36 disease
37 dosimetry protocols
38 efficacy
39 emitters
40 first-line treatment
41 follicular lymphoma
42 frontline treatment
43 good physical properties
44 hemopathies
45 high-dose treatment
46 humanization
47 humanized mAb
48 imaging
49 index
50 induction chemotherapy
51 injected activity
52 large molecules
53 lutetium-177
54 lymphoma
55 mAbs
56 metastatic disease
57 microscopic clusters
58 molecular targets
59 molecules
60 monoclonal antibodies
61 multiple myeloma
62 myeloma
63 new advances
64 new molecular targets
65 patients
66 physical properties
67 positron emission tomography (PET) imaging
68 possibility
69 practice
70 preclinical studies
71 pretargeting approach
72 products
73 promising clinical efficacy
74 promising results
75 properties
76 protocol
77 quantitative positron emission tomography (PET) imaging
78 radiation
79 radioimmunotherapy
80 refractory follicular lymphoma
81 results
82 safety
83 safety of radioimmunotherapy
84 setting
85 solid tumors
86 stable chelates
87 study
88 target
89 technique
90 theoretical possibility
91 therapeutic index
92 tiuxetan
93 today
94 tomography imaging
95 treatment
96 treatment of cancer
97 treatment of patients
98 tumor cells
99 tumors
100 use
101 years
102 schema:name New Advances in Radioimmunotherapy for the Treatment of Cancers
103 schema:pagination 441-460
104 schema:productId N1b4668f30b7e4200a6b2e33d22722626
105 Nf909b2c353fc44a0a9d5b0322c441276
106 schema:publisher Nc3a964b4bf044727a68bf53b52cb8099
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034466597
108 https://doi.org/10.1007/978-3-662-44946-2_25
109 schema:sdDatePublished 2022-12-01T06:54
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher Nb756f2275f6f42bc8a64c11f01b8f936
112 schema:url https://doi.org/10.1007/978-3-662-44946-2_25
113 sgo:license sg:explorer/license/
114 sgo:sdDataset chapters
115 rdf:type schema:Chapter
116 N1b4668f30b7e4200a6b2e33d22722626 schema:name dimensions_id
117 schema:value pub.1034466597
118 rdf:type schema:PropertyValue
119 N1d3ec8283c1442edb6222313e21be4d3 rdf:first sg:person.01025400253.44
120 rdf:rest N75771bfdad474ab5a23e2dcf1ada4a9b
121 N5ba8c606960249b881fc7bf23791a557 rdf:first sg:person.01112242163.57
122 rdf:rest Nbef213d2d43c44c4b7c57b774f6d6348
123 N75771bfdad474ab5a23e2dcf1ada4a9b rdf:first sg:person.01224071104.01
124 rdf:rest N974996013c834eba88711c7b95e4772f
125 N8b9d7811e9254c60a5bfe1d8d98000cc rdf:first sg:person.0653324404.03
126 rdf:rest Nfa0d3f318b3848afb7bb6179cfbec4cd
127 N941e22008330468bbe7f4613859bd94d rdf:first sg:person.01334456404.06
128 rdf:rest N1d3ec8283c1442edb6222313e21be4d3
129 N95e9411ae3f94e01b5834d73ce15bc12 rdf:first sg:person.0623457423.87
130 rdf:rest N941e22008330468bbe7f4613859bd94d
131 N974996013c834eba88711c7b95e4772f rdf:first sg:person.01001654663.28
132 rdf:rest rdf:nil
133 N9957f0500ab44e2cb6a86518bacedff3 rdf:first Ne7a9e7923fbe470792c57bbf327b819c
134 rdf:rest rdf:nil
135 Na45d50cf74394a5bbdb26685e59e3919 schema:isbn 978-3-662-44945-5
136 978-3-662-44946-2
137 schema:name Cancer Immunology
138 rdf:type schema:Book
139 Nb756f2275f6f42bc8a64c11f01b8f936 schema:name Springer Nature - SN SciGraph project
140 rdf:type schema:Organization
141 Nbef213d2d43c44c4b7c57b774f6d6348 rdf:first sg:person.01244363026.52
142 rdf:rest Nce7ead1de77344af9291fe9ff82138d4
143 Nc14f3c36518f470f92dc9c8de5468d6c rdf:first sg:person.01200407127.59
144 rdf:rest N5ba8c606960249b881fc7bf23791a557
145 Nc3a964b4bf044727a68bf53b52cb8099 schema:name Springer Nature
146 rdf:type schema:Organisation
147 Nce7ead1de77344af9291fe9ff82138d4 rdf:first sg:person.01225557150.10
148 rdf:rest Nfb68127789924245a18efe0894108967
149 Nd9a24b0ddd65437d8e35eb3cceb3738f rdf:first sg:person.01240530667.47
150 rdf:rest Nc14f3c36518f470f92dc9c8de5468d6c
151 Ne7a9e7923fbe470792c57bbf327b819c schema:familyName Rezaei
152 schema:givenName Nima
153 rdf:type schema:Person
154 Nf909b2c353fc44a0a9d5b0322c441276 schema:name doi
155 schema:value 10.1007/978-3-662-44946-2_25
156 rdf:type schema:PropertyValue
157 Nfa0d3f318b3848afb7bb6179cfbec4cd rdf:first sg:person.01212260416.00
158 rdf:rest Nd9a24b0ddd65437d8e35eb3cceb3738f
159 Nfb68127789924245a18efe0894108967 rdf:first sg:person.01105624024.07
160 rdf:rest N95e9411ae3f94e01b5834d73ce15bc12
161 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
162 schema:name Medical and Health Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
165 schema:name Oncology and Carcinogenesis
166 rdf:type schema:DefinedTerm
167 sg:person.01001654663.28 schema:affiliation grid-institutes:None
168 schema:familyName Barbet
169 schema:givenName Jacques
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28
171 rdf:type schema:Person
172 sg:person.01025400253.44 schema:affiliation grid-institutes:grid.4817.a
173 schema:familyName Gestin
174 schema:givenName Jean-François
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025400253.44
176 rdf:type schema:Person
177 sg:person.01105624024.07 schema:affiliation grid-institutes:grid.4817.a
178 schema:familyName Davodeau
179 schema:givenName François
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105624024.07
181 rdf:type schema:Person
182 sg:person.01112242163.57 schema:affiliation grid-institutes:None
183 schema:familyName Ferrer
184 schema:givenName Ludovic
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112242163.57
186 rdf:type schema:Person
187 sg:person.01200407127.59 schema:affiliation grid-institutes:grid.277151.7
188 schema:familyName Carlier
189 schema:givenName Thomas
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200407127.59
191 rdf:type schema:Person
192 sg:person.01212260416.00 schema:affiliation grid-institutes:grid.277151.7
193 schema:familyName Bodet-Milin
194 schema:givenName Caroline
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212260416.00
196 rdf:type schema:Person
197 sg:person.01224071104.01 schema:affiliation grid-institutes:grid.4817.a
198 schema:familyName Chérel
199 schema:givenName Michel
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224071104.01
201 rdf:type schema:Person
202 sg:person.01225557150.10 schema:affiliation grid-institutes:None
203 schema:familyName Haddad
204 schema:givenName Férid
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225557150.10
206 rdf:type schema:Person
207 sg:person.01240530667.47 schema:affiliation grid-institutes:None
208 schema:familyName Rousseau
209 schema:givenName Caroline
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47
211 rdf:type schema:Person
212 sg:person.01244363026.52 schema:affiliation grid-institutes:grid.418682.1
213 schema:familyName Chouin
214 schema:givenName Nicolas
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244363026.52
216 rdf:type schema:Person
217 sg:person.01334456404.06 schema:affiliation grid-institutes:grid.277151.7
218 schema:familyName Faivre-Chauvet
219 schema:givenName Alain
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334456404.06
221 rdf:type schema:Person
222 sg:person.0623457423.87 schema:affiliation grid-institutes:None
223 schema:familyName Chatal
224 schema:givenName Jean-François
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623457423.87
226 rdf:type schema:Person
227 sg:person.0653324404.03 schema:affiliation grid-institutes:None
228 schema:familyName Kraeber-Bodéré
229 schema:givenName Françoise
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03
231 rdf:type schema:Person
232 grid-institutes:None schema:alternateName Department of Nuclear Medicine, ICO-René Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France
233 GIP Arronax, 1, rue Aronnax – CS 10112, 44817, Saint-Herblain, France
234 schema:name Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, U892 8 quai Moncousu, 44007, Nantes, France
235 Department of Nuclear Medicine, ICO-René Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France
236 Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France
237 Department of Nuclear Oncology, Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, U892 8 quai Moncousu, 44007, Nantes, France
238 Department of Physics, Subatech, Ecole des Mînes, University of Nantes, Site de la Chantrerie 4 rue Alfred Kastler, BP 20722, 44307, Nantes, France
239 GIP Arronax, 1, rue Aronnax – CS 10112, 44817, Saint-Herblain, France
240 rdf:type schema:Organization
241 grid-institutes:grid.277151.7 schema:alternateName Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France
242 schema:name Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, U892 8 quai Moncousu, 44007, Nantes, France
243 Department of Nuclear Medicine, University Hospital, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France
244 rdf:type schema:Organization
245 grid-institutes:grid.418682.1 schema:alternateName AMaROC Research Group, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Site de la Chantrerie – CS 40706, 44307, Nantes, France
246 schema:name AMaROC Research Group, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Site de la Chantrerie – CS 40706, 44307, Nantes, France
247 Department of Physics, ONIRIS (Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering), Site de la Chantrerie, Route de Gachet, 44300, Nantes, France
248 rdf:type schema:Organization
249 grid-institutes:grid.4817.a schema:alternateName Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, U892 8 quai Moncousu, 44007, Nantes, France
250 Department of Nuclear Oncology, Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, U892 8 quai Moncousu, 44007, Nantes, France
251 INSERM UMR892 - CNRS UMR6299 - CRCNA (Equipe 13), Institut de Recherche en Santé de l’Université de Nantes, 8 quai Moncousu, BP 70721, 44007, Nantes, France
252 schema:name Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, U892 8 quai Moncousu, 44007, Nantes, France
253 Department of Nuclear Medicine, ICO-René Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France
254 Department of Nuclear Oncology, Centre de Recherche en Cancérologie de Nantes-Angers Inserm, Université de Nantes, U892 8 quai Moncousu, 44007, Nantes, France
255 Department of Nuclear Oncology, INSERM UMR892 - CNRS UMR6299 - CRCNA (Equipe 13), Institut de Recherche en Santé de l’Université de Nantes, 8 quai Moncousu, BP 70721, 44007, Nantes, France
256 INSERM UMR892 - CNRS UMR6299 - CRCNA (Equipe 13), Institut de Recherche en Santé de l’Université de Nantes, 8 quai Moncousu, BP 70721, 44007, Nantes, France
257 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...